Apogee Therapeutics, Inc. Contracts & Agreements
30 Contracts & Agreements
- Business Finance (8 contracts)
- Business Operations (2)
- Human Resources (8)
- Intellectual Property (5)
- Uncategorized (7)
- Description of the Companys Securities (Filed With SEC on March 5, 2024)
- Equity Incentive Plan Form of Restricted Unit Award Grant Notice (Filed With SEC on March 5, 2024)
- Form of Underwriting Agreement (Filed With SEC on March 5, 2024)
- 2023 Option Agreement, dated November 9, 2023, by and between Paragon Therapeutics, Inc. and Apogee Therapeutics, Inc (Filed With SEC on November 13, 2023)
- Contribution and Exchange Agreement, effective July 13, 2023, by and among the Company and the Unit Holders named therein (Filed With SEC on August 28, 2023)
- Registration Rights Agreement, dated July 13, 2023, by and among the Company and the Investors named therein (Filed With SEC on August 28, 2023)
- Employment Agreement, dated August 25, 2023, by and between Apogee Therapeutics, Inc. and Michael Henderson, M.D (Filed With SEC on August 28, 2023)
- Employment Agreement, dated August 25, 2023, by and between Apogee Therapeutics, Inc. and Jane Pritchett Henderson (Filed With SEC on August 28, 2023)
- Employment Agreement, dated August 25, 2023, by and between Apogee Therapeutics, Inc. and Carl Dambkowski, M.D (Filed With SEC on August 28, 2023)
- Equity Incentive Plan (Filed With SEC on August 28, 2023)
- 2023 Equity Incentive Plan (Filed With SEC on July 10, 2023)
- 2023 Employee Stock Purchase Plan (Filed With SEC on July 10, 2023)
- Form of Underwriting Agreement (Filed With SEC on July 3, 2023)
- Form of Contribution and Exchange Agreement (Filed With SEC on July 3, 2023)
- Form of Registration Rights Agreement (Filed With SEC on July 3, 2023)
- Form of Indemnification Agreement for directors and executive officers (Filed With SEC on July 3, 2023)
- Form of 2023 Equity Incentive Plan (Filed With SEC on July 3, 2023)
- Form of 2023 Employee Stock Purchase Plan (Filed With SEC on July 3, 2023)
- Employment Agreement, dated June (Filed With SEC on June 22, 2023)
- Employee Offer Letter, effective as of August 28, 2022, by and between Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) and Carl Dambkowski, M.D (Filed With SEC on June 22, 2023)
- Employee Offer Letter, effective as of January 12, 2023, by and between Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) and Jane Pritchett Henderson (Filed With SEC on June 22, 2023)
- Antibody Discovery and Option agreement, dated February 24, 2022, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) (Filed With SEC on June 22, 2023)
- Amendment No. 1 to Antibody Discovery and Option agreement, dated November 10, 2022, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee... (Filed With SEC on June 22, 2023)
- IL-13 License Agreement, dated November 4, 2022, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) (Filed With SEC on June 22, 2023)
- Amendment No. 1 to IL-13 License Agreement, dated November 10, 2022, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) (Filed With SEC on June 22, 2023)
- IL-4R License Agreement, dated April 3, 2023, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) (Filed With SEC on June 22, 2023)
- OX40L License Agreement, dated April 28, 2023, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) (Filed With SEC on June 22, 2023)
- Biologics Master Services Agreement, dated June 20, 2022 by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on June 22, 2023)
- Cell Line License Agreement, effective as of June 20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on June 22, 2023)
- Novation Agreement, dated April 1, 2023, by and between Paragon Therapeutics, Inc., Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) and WuXi Biologics (Hong Kong) Limited (Filed With SEC on June 22, 2023)
